Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma

American Journal of Gastroenterology

Volumn 94, Issue 11, 1999, Pages 3314-3319

  Trojan, Joerg ^b   Schroeder, Oliver ^b   Raedle, Jochen ^b   Baum, Richard P ^b   Herrmann, Guenter ^a   Jacobi, Volkmar ^a   Zeuzem, Stefan ^b  

^a GOETHE UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; FLUORINE 18; FLUORODEOXYGLUCOSE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; GLUCOSE METABOLISM; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; TUMOR SUPPRESSOR PROTEIN P53; WHOLE-BODY COUNTING;

EID: 0032754122     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(99)00603-6     Document Type: Article

References (32)

1. Di Bisceglie A.M. Hepatitis C and hepatocellular carcinoma. Hepatology. 26:(suppl 1):1997;34-38.
2. Haydon G.H., Hayes P.C. Screening for hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 8:1996;856-860.
3. Curry G.W., Beattie A.D. Pathogenesis of primary hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 8:1996;850-855.
4. Bourdon J.C., D'Errico A., Paterlini P., et al. p53 protein accumulation in European hepatocellular carcinoma is not always dependent on p53 gene mutation. Gastroenterology. 108:1995;1176-1182.
5. Ng I.O., Lai E.C., Chan A.S., et al. Overexpression of p53 in hepatocellular carcinomas A clinicopathological and prognostic correlation . J Gastroenterol Hepatol. 10:1995;250-255.
6. Raedle J., Oremek G., Truschnowitsch, et al. Clinical evaluation of autoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma. Eur J Cancer. 34:1998;1198-1203.
7. Zornig C., Broelsch C.E. Impact of staging on the treatment of hepatocellular carcinoma. Endoscopy. 25:1993;138-142.
8. Trojan J., Raedle J., Zeuzem S. Serum tests for diagnosis and follow-up of hepatocellular carcinoma after treatment. Digestion. 59:(suppl 2):1998;72-74.
9. Collier J., Sherman M. Screening for hepatocellular carcinoma. Hepatology. 27:1998;273-278.
10. Dodd G.D., Miller W.J., Baron R.L., et al. Detection of malignant tumors in end-stage cirrhotic livers Efficacy of sonography as a screening technique . Am J Roentgenol. 159:1992;727-733.
11. Honda H., Onitsuka H., Murakami J., et al. Characteristic findings of hepatocellular carcinoma An evaluation with comparative study of US, CT and MRI . Gastrointest Radiol. 17:1992;245-249.
12. Winter T.C., Takayasu K., Muramatsu Y., et al. Early advanced hepatocellular evaluation of CT and MR appearance with pathologic correlation . Radiology. 192:1994;379-387.
13. Yu J.S., Kim K.W., Lee J.T., et al. MR imaging during arterial portography for assessment of hepatocellular carcinoma. Comparison with CT during arterial portography. Am J Roentgenol. 170:1998;1501-1506.
14. Hör G., Adams S., Baum R.P., et al. Impact of single photon emission computed tomography and positron emission tomography on diagnostic oncology. Diagn Oncol. 4:1997;297-321.
15. Rigo P., Paulus P., Kaschten B.J., et al. Oncological applications of positron emission tomography with fluorine-18-fluorodeoxyglucose. Eur J Nucl Med. 23:1996;1641-1674.
16. Schroeder O., Trojan J., Zeuzem S., et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection. Nuklearmedizin. 37:1998;279-285.
17. Dimitrakopoulou-Strauss A., Gutzler F., Strauss L.G., et al. PET studies with C-11 ethanol in intratumoral therapy of hepatocellular carcinomas. Radiologe. 36:1996;744-749.
18. Okazumi S., Isono K., Enomoto K., et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET Characterization of tumor and assessment of effect of treatment . J Nucl Med. 33:1992;333-339.
19. Torizuka T., Tamaki N., Inokuma T., et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med. 35:1994;1965-1969.
20. Combs C.S., Lowe V.J., Wolverson M.K., et al. Positron emission tomography (PET) scanning in the diagnosis of hepatocellular carcinoma (HCC). Hepatology. 26:(suppl 1):1997;242A.
21. Torizuka T., Tamaki N., Inokuma T., et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 36:1995;1811-1817.
22. Baron R.L., Oliver J.H., Dodd G.D., et al. Hepatocellular carcinoma Evaluation with biphasic, contrast-enhanced, helical CT . Radiology. 199:1996;505-511.
23. Edmonson H.A., Steiner P.E. Primary carcinoma of the liver A study of 100 cases among 48900 necropsies . Cancer. 7:1954;462-503.
24. Midgley C.A., Fisher C.J., Bartek J., et al. Analysis of p53 expression in human tumors An antibody raised against human p53 expressed in Esherichia coli . J Cell Sci. 101:1992;183-189.
25. Delbeke D., Martin W.H., Sandler M.P., et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 133:1998;510-515.
26. 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med. 25:1998;1255-1260.
27. Dietrich C.F., Lee J.H., Herrmann G., et al. Enlargement of perihepatic lymph nodes in relation to liver histology and viremia in patients with chronic hepatitis C. Hepatology. 26:1997;467-472.
28. Dodd G.D. 3rd, Baron R.L., Oliver J.H. 3rd, et al. Enlarged abdominal lymph nodes in end-stage cirrhosis CT-histopathologic correlation in 507 patients . Radiology. 203:1997;127-130.
29. Sasaki Y., Imaoka S., Ishiguro S., et al. Clinical features of small hepatocellular carcinomas as assessed by histologic grades. Surgery. 119:1996;252-260.
30. Grobholz R., Hacker H.J., Thorens B., et al. Reduction in the expression of glucose transporter protein GLUT 2 in preneoplastic and neoplastic hepatic lesions and reexpression of GLUT 1 in late stages of hepatocarcinogenesis. Cancer Res. 53:1993;4204-4211.
31. Stuart K.E., Anand A.J., Jenkins R.L. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer. 77:1996;2217-2222.
32. Peng S.Y., Lai P.L., Chu J.S., et al. Expression and hypomethylation of α-fetoprotein gene in unicentric and multicentric human hepatocellular carcinoma. Hepatology. 17:1993;35-41.